UPDATE: CRT Capital Initiates Coverage on OncoGenex
CRT Capital Thursday morning ratings report included a coverage initiation by analyst Arlinda Lee on Oncogenex Pharmaceuticals (NASDAQ: OGXI) with a Buy rating and price target of $20.
The highlight for OGXI includes phase 3 trials of Curtisen and subsequent partnership with Teva, along with phase 2 trials of Apatorsen.
The report notes "The basis for our Buy rating is our optimism for a positive outcome from ongoing pivotal Phase 3 SYNERGY trial in castrate resistant prostate cancer (CRPC) in mid-2014. We expect FDA filing in 2H14 and approval in 20145. We also expect rapid uptake of custirsen to reach peak 35% penetration the US and 30% in EU."
OGXI closed the previous trading session at $11.51 and is currently trading around the $11.76 mark.
Latest Ratings for OGXI
|Dec 2015||Stifel Nicolaus||Downgrades||Buy||Hold|
|Sep 2015||RBC Capital||Maintains||Sector Perform|
|Apr 2014||Stifel Nicolaus||Maintains||Buy|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.